Context Therapeutics Inc.
Data quality: 83%
CNTX
Nasdaq
Manufacturing
Chemicals
$2.62
▼
$0.02
(-0.76%)
Mkt Cap: 240.72 M
Price
$2.62
Mkt Cap
240.72 M
Day Range
$2.59 — $2.83
52-Week Range
$0.49 — $3.62
Volume
440,294
Open $2.65
50D / 200D Avg
$2.57
2.01% above
50D / 200D Avg
$1.41
85.76% above
Quick Summary
Key Takeaways
Negative free cash flow of -26.42 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-46.40%
Above sector avg (-53.41%)
ROIC-40.27%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio13.10
Interest CoverageN/A
Valuation
PE (TTM)
-6.66
Below sector avg (-1.48)
P/B Ratio3.29
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -6.7 | -1.5 |
| P/B | 3.3 | 1.6 |
| ROE % | -46.4 | -53.4 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -36.12 M |
| ROE | -46.40% | ROA | -43.42% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -26.42 M |
| ROIC | -40.27% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 13.10 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 73.02 M | Tangible Book Value | 73.17 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -6.66 | Forward P/E | N/A |
| P/B Ratio | 3.29 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -10.97% | ||
| Market Cap | 240.72 M | Enterprise Value | 163.79 M |
| Per Share | |||
| EPS (Diluted TTM) | -0.38 | Revenue / Share | N/A |
| FCF / Share | -0.29 | OCF / Share | -0.29 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 73.14% |
| SBC-Adj. FCF | -27.64 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -36.12 M | -26.73 M | -23.96 M | -14.84 M | -10.46 M |
| EPS (Diluted) | -0.38 | -0.46 | -1.50 | -0.93 | -3.69 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -39.70 M | -29.92 M | -25.07 M | -15.38 M | -10.53 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | — | — | — | — | — |
| SG&A Expenses | — | — | — | — | — |
| D&A | 16,251.0 | 10,881.0 | 12,044.0 | 9,268.0 | — |
| Interest Expense | — | — | 1.16 M | 547,268.0 | 64,240.0 |
| Income Tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 68.49 M | 98.13 M | 16.06 M | 37.97 M | 51.31 M |
| Total Liabilities | 8.02 M | 2.86 M | 4.19 M | 3.21 M | 3.03 M |
| Shareholders' Equity | 60.47 M | 95.27 M | 11.87 M | 34.76 M | 48.27 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 66.00 M | 94.43 M | 14.45 M | 35.50 M | 49.64 M |
| Current Assets | 68.35 M | 97.90 M | 16.05 M | 37.85 M | 51.26 M |
| Current Liabilities | 8.02 M | 2.75 M | 4.19 M | 3.21 M | 3.03 M |
{"event":"ticker_viewed","properties":{"ticker":"CNTX","listing_kind":"stock","pathname":"/stocks/cntx","exchange":"Nasdaq","country":"US"}}